Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.

A Hochhaus, T Masszi, F J Giles, J Radich, David Ross, M T Gomez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia-Gutierrez, Norbert Gattermann, W Wiktor-Jedrzejczak, Philipp Le Coutre, Bruno Martino, Susanne Saussele, H D Menssen, W Deng, Nancy Krunic, Veronique Bedoucha, Guiseppe Saglio

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with MR4.5 (BCR-ABL1 <0.0032% on the International Scale (BCR-ABL1IS)) and ≥ 2 years of frontline nilotinib therapy were enrolled. Patients with sustained deep molecular response during the 1-year nilotinib consolidation phase were eligible to stop treatment and enter the TFR phase. Patients with loss of major molecular response (MMR; BCR-ABL1IS ≤0.1%) during the TFR phase reinitiated nilotinib. In total, 215 patients entered the consolidation phase, of whom 190 entered the TFR phase. The median duration of nilotinib before stopping treatment was 43.5 months. At 48 weeks after stopping nilotinib, 98 patients (51.6%; 95% confidence interval, 44.2-58.9%) remained in MMR or better (primary end point). Of the 86 patients who restarted nilotinib in the treatment reinitiation phase after loss of MMR, 98.8% and 88.4%, respectively, regained MMR and MR 4.5 by the data cutoff date. Consistent with prior reports of imatinib-treated patients, musculoskeletal pain-related events were reported in 24.7% of patients in the TFR phase (consolidation phase, 16.3%).

Original languageEnglish
Pages (from-to)1525-1531
Number of pages7
JournalLeukemia
Volume31
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017
Externally publishedYes

Bibliographical note

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Keywords

  • chronic myeloid leukemia
  • nilotinib
  • Treatment-free remission
  • ENESTfreedom study

Fingerprint Dive into the research topics of 'Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.'. Together they form a unique fingerprint.

  • Cite this

    Hochhaus, A., Masszi, T., Giles, F. J., Radich, J., Ross, D., Gomez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., Wiktor-Jedrzejczak, W., Le Coutre, P., Martino, B., Saussele, S., Menssen, H. D., Deng, W., Krunic, N., Bedoucha, V., & Saglio, G. (2017). Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia, 31(7), 1525-1531. https://doi.org/10.1038/leu.2017.63